Cholesterol: A friend to viruses

References

• Chu BB, Liao YC, Qi W, et al. Cholesterol transport through lysosome-peroxisome membrane contacts. Cell. 2015;161(2):291–306. doi:10.1016/j.cell.2015.02.019.
   PubMed Web of Science ®Google Scholar
• Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: Cholesterol and beyond. Nat Rev Neurosci. 2011;12(5):284–296. doi:10.1038/nrn3012.
   PubMed Web of Science ®Google Scholar
• Goossens P, Rodriguez-Vita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29(6):1376–1389.e4. e1374. doi:10.1016/j.cmet.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Hoppstädter J, Dembek A, Höring M, et al. Dysregulation of cholesterol homeostasis in human lung cancer tissue and tumour-associated macrophages. EBioMed. 2021;72:103578. doi:10.1016/j.ebiom.2021.103578.
   PubMed Web of Science ®Google Scholar
• Sag D, Cekic C, Wu R, et al. The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat Commun. 2015;6(1):6354. doi:10.1038/ncomms7354.
   PubMedGoogle Scholar
• Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe. 2007;2(4):229–239. doi:10.1016/j.chom.2007.09.003.
   PubMed Web of Science ®Google Scholar
• Blanc M, Hsieh WY, Robertson KA, et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol. 2011;9(3):e1000598. doi:10.1371/journal.pbio.1000598.
   PubMed Web of Science ®Google Scholar
• Petersen J, Drake MJ, Bruce EA, et al. The major cellular sterol regulatory pathway is required for Andes virus infection. PLoS Pathog. 2014;10(2):e1003911. doi:10.1371/journal.ppat.1003911.
   PubMed Web of Science ®Google Scholar
• Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA. 2005;102(7):2561–2566. doi:10.1073/pnas.0409834102.
   PubMed Web of Science ®Google Scholar
• Osuna-Ramos JF, Reyes-Ruiz JM, Del Angel, RM. The role of host cholesterol during flavivirus infection. Front Cell Infect Microbiol. 2018;8:388. doi:10.3389/fcimb.2018.00388.
   PubMed Web of Science ®Google Scholar
• Nagy PD. Viral sensing of the subcellular environment regulates the assembly of new viral replicase complexes during the course of infection. J Virol. 2015;89(10):5196–5199. doi:10.1128/JVI.02973-14.
   PubMed Web of Science ®Google Scholar
• Yuan S, Chu H, Chan JF, et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat Commun. 2019;10(1):120. doi:10.1038/s41467-018-08015-x.
   PubMed Web of Science ®Google Scholar
• Ilnytska O, Santiana M, Hsu NY, et al. Enteroviruses harness the cellular endocytic machinery to remodel the host cell cholesterol landscape for effective viral replication. Cell Host Microbe. 2013;14(3):281–293. doi:10.1016/j.chom.2013.08.002.
   PubMed Web of Science ®Google Scholar
• Wang C, Gale MJr., Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005;18(4):425–434. doi:10.1016/j.molcel.2005.04.004.
   PubMed Web of Science ®Google Scholar
• Cui HL, Grant A, Mukhamedova N, et al. HIV-1 Nef mobilizes lipid rafts in macrophages through a pathway that competes with ABCA1-dependent cholesterol efflux. J Lipid Res. 2012;53(4):696–708. doi:10.1194/jlr.M023119.
   PubMed Web of Science ®Google Scholar
• York AG, Williams KJ, Argus JP, et al. Limiting cholesterol biosynthetic flux spontaneously engages type I IFN signaling. Cell. 2015;163(7):1716–1729. doi:10.1016/j.cell.2015.11.045.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Bergeron M, Méthot S, et al . Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol. 2005;18(3):474–489. doi:10.1089/vim.2005.18.474.
   PubMed Web of Science ®Google Scholar
• Rzouq F, Alahdab F, Olyaee M. Statins and hepatitis C virus infection: An old therapy with new scope. Am J Med Sci. 2014;348(5):426–430. doi:10.1097/MAJ.0000000000000291.
   PubMed Web of Science ®Google Scholar
• Sezgin E, Levental I, Mayor S, Eggeling C. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. Nat Rev Mol Cell Biol. 2017;18(6):361–374. doi:10.1038/nrm.2017.16.
   PubMed Web of Science ®Google Scholar
• Kuzu OF, Noory MA, Robertson GP. The role of cholesterol in cancer. Cancer Res. 2016;76(8):2063–2070. doi:10.1158/0008-5472.CAN-15-2613.
   PubMed Web of Science ®Google Scholar
• Burnett JR, Hooper AJ, Hegele RA. Remnant cholesterol and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2020;76(23):2736–2739. doi:10.1016/j.jacc.2020.10.029.
   PubMed Web of Science ®Google Scholar
• Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie. 2004;86(11):839–848. doi:10.1016/j.biochi.2004.09.018.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124(1):35–46. doi:10.1016/j.cell.2005.12.022.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell. 2002;10(2):237–245. doi:10.1016/s1097-2765(02)00591-9.
   PubMed Web of Science ®Google Scholar
• Brown MS, Radhakrishnan A, Goldstein JL. Retrospective on cholesterol homeostasis: The central role of scap. Annu Rev Biochem. 2018;87(1):783–807. doi:10.1146/annurev-biochem-062917-011852.
   PubMedGoogle Scholar
• Lee SJ, Sekimoto T, Yamashita E, et al. The structure of importin-ß bound to SREBP-2 nuclear import of a transcription factor. Science. 2003;302(5650):1571–1575. doi:10.1126/science.1088372.
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HJ, Zhu LJ, et al. Niemann–Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201–1204. doi:10.1126/science.1093131.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Ge L, Qi W, et al. The N-terminal domain of NPC1L1 protein binds cholesterol and plays essential roles in cholesterol uptake. J Biol Chem. 2011;286(28):25088–25097. doi:10.1074/jbc.M111.244475.
   PubMed Web of Science ®Google Scholar
• Li P-S, Fu Z-Y, Zhang Y-Y, et al. The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1. Nat Med. 2013;20(1):80–86. doi:10.1038/nm.3417.
   PubMed Web of Science ®Google Scholar
• Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001;292(5520):1394–1398. doi:10.1126/science.1060458.
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Abi-Mosleh L, Wang ML, et al. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 2009;137(7):1213–1224. doi:10.1016/j.cell.2009.03.049.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ. Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle. 2022;21(11):1121–1139. doi:10.1080/15384101.2022.2042777.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Brewer HBJr., Davidson WS, et al. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905–1919. doi:10.1161/CIRCULATIONAHA.111.066589.
   PubMed Web of Science ®Google Scholar
• Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001;276(26):23742–23747. doi:10.1074/jbc.M102348200.
   PubMed Web of Science ®Google Scholar
• Tarling EJ, Edwards PA. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc Natl Acad Sci USA. 2011;108(49):19719–19724. doi:10.1073/pnas.1113021108.
   PubMed Web of Science ®Google Scholar
• Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005;1(2):121–131. doi:10.1016/j.cmet.2005.01.002.
   PubMed Web of Science ®Google Scholar
• Kobayashi A, Takanezawa Y, Hirata T, et al. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. J Lipid Res. 2006;47(8):1791–1802. doi:10.1194/jlr.M500546-JLR200.
   PubMed Web of Science ®Google Scholar
• Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem. 2003;278(48):48275–48282. doi:10.1074/jbc.M310223200.
   PubMed Web of Science ®Google Scholar
• Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang, TY. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. J Steroid Biochem Mol Biol. 2015;151:102–107. doi:10.1016/j.jsbmb.2014.09.008.
   PubMed Web of Science ®Google Scholar
• Chang TY, Chang CC, Ohgami N, Yamauchi Y. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol. 2006;22(1):129–157. doi:10.1146/annurev.cellbio.22.010305.104656.
   PubMedGoogle Scholar
• Yu C, Chen J, Lin S, Liu J, Chang CC, Chang, TY. Human acyl-CoA:cholesterol acyltransferase-1 is a homotetrameric enzyme in intact cells and in vitro. J Biol Chem. 1999;274(51):36139–36145. doi:10.1074/jbc.274.51.36139.
   PubMed Web of Science ®Google Scholar
• Chang CC, Sakashita N, Ornvold K, et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem. 2000;275(36):28083–28092. doi:10.1074/jbc.M003927200.
   PubMed Web of Science ®Google Scholar
• Liu J, Chang CC, Westover EJ, Covey DF, Chang, TY. Investigating the allosterism of acyl-CoA:cholesterol acyltransferase (ACAT) by using various sterols: In vitro and intact cell studies. Biochem J. 2005;391(Pt 2):389–397. doi:10.1042/BJ20050428.
   PubMedGoogle Scholar
• Romeo S. ACAT2 as a novel therapeutic target to treat fatty liver disease. J Intern Med. 2022;292(2):175–176. doi:10.1111/joim.13460.
   PubMed Web of Science ®Google Scholar
• Parini P, Davis M, Lada AT, et al. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation. 2004;110(14):2017–2023. doi:10.1161/01.CIR.0000143163.76212.0B.
   PubMed Web of Science ®Google Scholar
• Cases S, Novak S, Zheng YW, et al. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem. 1998;273(41):26755–26764. doi:10.1074/jbc.273.41.26755.
   PubMed Web of Science ®Google Scholar
• Branche E, Wang YT, Viramontes KM, et al. SREBP2-dependent lipid gene transcription enhances the infection of human dendritic cells by Zika virus. Nat Commun. 2022;13(1):5341. doi:10.1038/s41467-022-33041-1.
   PubMed Web of Science ®Google Scholar
• Lee W, Ahn JH, Park HH, et al. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Signal Transduct Target Ther. 2020;5(1):186. doi:10.1038/s41392-020-00292-7.
   PubMed Web of Science ®Google Scholar
• Li M, Wang Q, Liu SA, et al. MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein. World J Gastroenterol. 2015;21(15):4517–4525. doi:10.3748/wjg.v21.i15.4517.
   PubMed Web of Science ®Google Scholar
• Zhang F, Sodroski C, Cha H, Li Q, Liang TJ. Infection of hepatocytes with HCV increases cell surface levels of heparan sulfate proteoglycans, uptake of cholesterol and lipoprotein, and virus entry by up-regulating SMAD6 and SMAD7. Gastroenterology. 2017;152(1):257–270.e7. e257. doi:10.1053/j.gastro.2016.09.033.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li M, Ma Y, et al. LncRNA NEAT1 potentiates SREBP2 activity to promote inflammatory macrophage activation and limit Hantaan virus propagation. Front Microbiol. 2022;13:849020. doi:10.3389/fmicb.2022.849020.
   PubMed Web of Science ®Google Scholar
• Soto-Acosta R, Mosso C, Cervantes-Salazar M, et al. The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity. Virology. 2013;442(2):132–147. doi:10.1016/j.virol.2013.04.003.
   PubMed Web of Science ®Google Scholar
• Geier A. Hepatitis B virus: The "metabolovirus" highjacks cholesterol and bile acid metabolism. Hepatology. 2014;60(5):1458–1460. doi:10.1002/hep.27224.
   PubMed Web of Science ®Google Scholar
• Zheng YH, Plemenitas A, Fielding CJ, et al. Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci USA. 2003;100(14):8460–8465. doi:10.1073/pnas.1437453100.
   PubMed Web of Science ®Google Scholar
• El Khoury P, Ghislain M, Villard EF, et al. Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: Impact of HAART. J Lipid Res. 2015;56(3):692–702. doi:10.1194/jlr.M054510.
   PubMed Web of Science ®Google Scholar
• Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006;4(11):e365. doi:10.1371/journal.pbio.0040365.
   PubMed Web of Science ®Google Scholar
• Ke W, Zhou Y, Lai Y, Long S, Fang L, Xiao S. Porcine reproductive and respiratory syndrome virus nsp4 positively regulates cellular cholesterol to inhibit type I interferon production. Redox Biol. 2022;49:102207. doi:10.1016/j.redox.2021.102207.
   PubMed Web of Science ®Google Scholar
• Zou X, Lin F, Yang Y, et al. Cholesterol biosynthesis modulates CSFV replication. Viruses. 2022;14(7):1450. doi:10.3390/v14071450.
   PubMed Web of Science ®Google Scholar
• Xiao J, Li W, Zheng X, et al. Targeting 7-dehydrocholesterol reductase integrates cholesterol metabolism and IRF3 activation to eliminate infection. Immunity. 2020;52(1):109–122.e6. doi:10.1016/j.immuni.2019.11.015.
   PubMed Web of Science ®Google Scholar
• Blanc M, Hsieh WY, Robertson KA, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity. 2013;38(1):106–118. doi:10.1016/j.immuni.2012.11.004.
   PubMed Web of Science ®Google Scholar
• Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in relation to COVID-19: Should we care about it? J Clin Med. 2020;9(6):1909. doi:10.3390/jcm9061909.
   PubMed Web of Science ®Google Scholar
• Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(2):158849. doi:10.1016/j.bbalip.2020.158849.
   PubMed Web of Science ®Google Scholar
• Wei C, Wan L, Yan Q, et al. HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry. Nat Metab. 2020;2(12):1391–1400. doi:10.1038/s42255-020-00324-0.
   PubMedGoogle Scholar
• Yin J, Glende J, Schwegmann-Wessels C, et al. Cholesterol is important for a post-adsorption step in the entry process of transmissible gastroenteritis virus. Antiviral Res. 2010;88(3):311–316. doi:10.1016/j.antiviral.2010.10.002.
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol. 2013;369:87–112. doi:10.1007/978-3-642-27340-7_4.
   PubMed Web of Science ®Google Scholar
• Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins–impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5(5):1292–1324. doi:10.3390/v5051292.
   PubMed Web of Science ®Google Scholar
• Lee J, Kreutzberger AJB, Odongo L, et al. Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry. Nat Struct Mol Biol. 2021;28(2):181–189. doi:10.1038/s41594-020-00548-4.
   PubMed Web of Science ®Google Scholar
• San-Juan-Vergara H, Sampayo-Escobar V, Reyes N, et al. Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells. J Virol. 2012;86(3):1832–1843. doi:10.1128/JVI.06274-11.
   PubMed Web of Science ®Google Scholar
• Contreras EM, Johnston GP, Buchholz DW, et al. Roles of cholesterol in early and late steps of the Nipah virus membrane fusion cascade. J Virol. 2021;95(6):e02323-20. doi:10.1128/JVI.02323-20.
   PubMed Web of Science ®Google Scholar
• Wudiri GA, Schneider SM, Nicola AV. Herpes simplex virus 1 envelope cholesterol facilitates membrane fusion. Front Microbiol. 2017;8:2383. doi:10.3389/fmicb.2017.02383.
   PubMed Web of Science ®Google Scholar
• Wudiri GA, Nicola AV. Cellular cholesterol facilitates the postentry replication cycle of herpes simplex virus 1. J Virol. 2017;91(14):e00445-17. doi:10.1128/JVI.00445-17.
   PubMed Web of Science ®Google Scholar
• Kremer EJ, Haspot F, Lavault A, et al. Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner. PLoS One. 2012;7(4):e34795. doi:10.1371/journal.pone.0034795.
   PubMed Web of Science ®Google Scholar
• Raghu H, Sharma-Walia N, Veettil MV, et al. Lipid rafts of primary endothelial cells are essential for Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8-induced phosphatidylinositol 3-kinase and RhoA-GTPases critical for microtubule dynamics and nuclear delivery of viral DNA but dispensable for binding and entry. J Virol. 2007;81(15):7941–7959. doi:10.1128/jvi.02848-06.
   PubMed Web of Science ®Google Scholar
• Wang S, Li W, Hui H, et al. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. EMBO J. 2020;39(21):e106057. doi:10.15252/embj.2020106057.
   PubMed Web of Science ®Google Scholar
• Liu SY, Aliyari R, Chikere K, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity. 2013;38(1):92–105. doi:10.1016/j.immuni.2012.11.005.
   PubMed Web of Science ®Google Scholar
• Koonin EV, Dolja VV, Krupovic M, et al. Global organization and proposed megataxonomy of the virus world. Microbiol Mol Biol Rev. 2020;84(2):e00061–00019. doi:10.1128/MMBR.00061-19.
   PubMed Web of Science ®Google Scholar
• Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, et al. A review: Mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol. 2021;35:20587384211002621. doi:10.1177/:20587384211002621.
   PubMed Web of Science ®Google Scholar
• Dai J, Wang H, Liao Y, et al. Coronavirus infection and cholesterol metabolism. Front Immunol. 2022;13:791267. doi:10.3389/fimmu.2022.791267.
   PubMed Web of Science ®Google Scholar
• Ohashi H, Wang F, Stappenbeck F, et al. Identification of anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) oxysterol derivatives in vitro. Int J Mol Sci. 2021;22(6):3163. doi:10.3390/ijms22063163.
   PubMed Web of Science ®Google Scholar
• Ishikawa-Sasaki K, Nagashima S, Taniguchi K, et al. Model of OSBP-mediated cholesterol supply to aichi virus RNA replication sites involving protein-protein interactions among viral proteins, ACBD3, OSBP, VAP-A/B, and SAC1. J Virol. 2018;92(8):e01952-17. doi:10.1128/JVI.01952-17.
   PubMed Web of Science ®Google Scholar
• Xu N, Shen N, Wang X, et al. Protein prenylation and human diseases: A balance of protein farnesylation and geranylgeranylation. Sci China Life Sci. 2015;58(4):328–335. doi:10.1007/s11427-015-4836-1.
   PubMed Web of Science ®Google Scholar
• Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem. 2000;275(23):17221–17224. doi:10.1074/jbc.R000005200.
   PubMed Web of Science ®Google Scholar
• Bajimaya S, Hayashi T, Frankl T, et al. Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses. Virology. 2017;501:127–135. doi:10.1016/j.virol.2016.11.011.
   PubMed Web of Science ®Google Scholar
• Nayak DP, Hui EK, Barman S. Assembly and budding of influenza virus. Virus Res. 2004;106(2):147–165. doi:10.1016/j.virusres.2004.08.012.
   PubMed Web of Science ®Google Scholar
• Brown G, Jeffree CE, McDonald T, et al. Analysis of the interaction between respiratory syncytial virus and lipid-rafts in Hep2 cells during infection. Virology. 2004;327(2):175–185. doi:10.1016/j.virol.2004.06.038.
   PubMed Web of Science ®Google Scholar
• Chang TH, Segovia J, Sabbah A, et al. Cholesterol-rich lipid rafts are required for release of infectious human respiratory syncytial virus particles. Virology. 2012;422(2):205–213. doi:10.1016/j.virol.2011.10.029.
   PubMed Web of Science ®Google Scholar
• Bajimaya S, Frankl T, Hayashi T, Takimoto T. Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses. Virology. 2017;510:234–241. doi:10.1016/j.virol.2017.07.024.
   PubMed Web of Science ®Google Scholar
• Mazière JC, Landureau JC, Giral P, et al. Lovastatin inhibits HIV-1 expression inH9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother. 1994;48(2):63–67. doi:10.1016/0753-3322(94)90077-9.
   PubMed Web of Science ®Google Scholar
• Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9(9):1089–1097. doi:10.1038/ncb1631.
   PubMed Web of Science ®Google Scholar
• Campbell SM, Crowe SM, Mak J. Lipid rafts and HIV-1: From viral entry to assembly of progeny virions. J Clin Virol. 2001;22(3):217–227. doi:10.1016/s1386-6532(01)00193-7.
   PubMed Web of Science ®Google Scholar
• Liu B, Ma Y, Huang Y, et al. Inhibition of human cytomegalovirus particle maturation by activation of liver X receptor. Front Microbiol. 2022;13:846386. doi:10.3389/fmicb.2022.846386.
   PubMed Web of Science ®Google Scholar
• Li YJ, Chen CY, Yang JH, Chiu YF. Modulating cholesterol-rich lipid rafts to disrupt influenza A virus infection. Front Immunol. 2022;13:982264. doi:10.3389/fimmu.2022.982264.
   PubMed Web of Science ®Google Scholar
• Martyna A, Bahsoun B, Madsen JJ, et al. Cholesterol alters the orientation and activity of the influenza virus M2 amphipathic helix in the membrane. J Phys Chem B. 2020;124(31):6738–6747. doi:10.1021/acs.jpcb.0c03331.
   PubMed Web of Science ®Google Scholar
• Lu YE, Kielian M. Semliki forest virus budding: Assay, mechanisms, and cholesterol requirement. J Virol. 2000;74(17):7708–7719. doi:10.1128/jvi.74.17.7708-7719.2000.
   PubMed Web of Science ®Google Scholar
• Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA. 2001;98(24):13925–13930. doi:10.1073/pnas.241320298.
   PubMed Web of Science ®Google Scholar
• Feng P, Wang X, Zhu N, et al. Mono-ubiquitylated ORF45 mediates association of KSHV particles with internal lipid rafts for viral assembly and egress. PLoS Pathog. 2015;11(12):e1005332. doi:10.1371/journal.ppat.1005332.
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Soto-Acosta R, Bautista-Carbajal P, et al. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog. 2017;13(4):e1006257. doi:10.1371/journal.ppat.1006257.
   PubMed Web of Science ®Google Scholar
• Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011;474(7350):208–211. doi:10.1038/nature10168.
   PubMed Web of Science ®Google Scholar
• Sainz B, Barretto N, Martin DN, et al. Identification of the Niemann–Pick C1–like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012;18(2):281–285. doi:10.1038/nm.2581.
   PubMed Web of Science ®Google Scholar
• Li C, Deng YQ, Wang S, et al. 25-Hydroxycholesterol protects host against Zika virus infection and its associated microcephaly in a mouse model. Immunity. 2017;46(3):446–456. doi:10.1016/j.immuni.2017.02.012.
   PubMed Web of Science ®Google Scholar
• Civra A, Colzani M, Cagno V, et al. Modulation of cell proteome by 25-hydroxycholesterol and 27-hydroxycholesterol: A link between cholesterol metabolism and antiviral defense. Free Radic Biol Med. 2020;149:30–36. doi:10.1016/j.freeradbiomed.2019.08.031.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li G-L, Qi Y-L, et al. Pseudorabies virus inhibits expression of liver X receptors to assist viral infection. Viruses. 2022;14(3):514. doi:10.3390/v14030514.
   Web of Science ®Google Scholar
• Fasolato S, Pigozzo S, Pontisso P, et al. PCSK9 levels are raised in chronic HCV patients with hepatocellular carcinoma. J Clin Med. 2020;9(10):3134. doi:10.3390/jcm9103134.
   PubMed Web of Science ®Google Scholar
• Gan ES, Tan HC, Le DHT, et al. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J Clin Invest. 2020;130(10):5223–5234. doi:10.1172/JCI137536.
   PubMed Web of Science ®Google Scholar
• Li G, Su B, Fu P, et al. NPC1-regulated dynamic of clathrin-coated pits is essential for viral entry. Sci China Life Sci. 2021;65(2):341–361. doi:10.1007/s11427-021-1929-y.
   PubMed Web of Science ®Google Scholar
• Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. Nature. 2011;477(7364):340–343. doi:10.1038/nature10348.
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Chang C-Y, Ma H-H, et al. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine. 2014;32(35):4485–4494. doi:10.1016/j.vaccine.2014.06.043.
   PubMed Web of Science ®Google Scholar
• Sangeetha B, Krishnamoorthy AS, Sharmila D, et al. Molecular modelling of coat protein of the Groundnut bud necrosis tospovirus and its binding with Squalene as an antiviral agent: In vitro and in silico docking investigations. Int J Biol Macromol. 2021;189:618–634. doi:10.1016/j.ijbiomac.2021.08.143.
   PubMed Web of Science ®Google Scholar
• Villareal VA, Fu D, Costello DA, et al. Hepatitis C virus selectively alters the intracellular localization of desmosterol. ACS Chem Biol. 2016;11(7):1827–1833. doi:10.1021/acschembio.6b00324.
   PubMed Web of Science ®Google Scholar
• Costello DA, Villareal VA, Yang, PL. Desmosterol increases lipid bilayer fluidity during hepatitis C virus infection. ACS Infect Dis. 2016;2(11):852–862. doi:10.1021/acsinfecdis.6b00086.
   PubMed Web of Science ®Google Scholar
• Rodgers MA, Villareal VA, Schaefer EA, et al. Lipid metabolite profiling identifies desmosterol metabolism as a new antiviral target for hepatitis C virus. J Am Chem Soc. 2012;134(16):6896–6899. doi:10.1021/ja207391q.
   PubMed Web of Science ®Google Scholar
• Wudiri GA, Pritchard SM, Li H, et al. Molecular requirement for sterols in herpes simplex virus entry and infectivity. J Virol. 2014;88(23):13918–13922. doi:10.1128/jvi.01615-14.
   PubMed Web of Science ®Google Scholar
• Lembo D, Cagno V, Civra A, Poli G. Oxysterols: An emerging class of broad spectrum antiviral effectors. Mol Aspects Med. 2016;49:23–30. doi:10.1016/j.mam.2016.04.003.
   PubMed Web of Science ®Google Scholar
• Shrivastava-Ranjan P, Bergeron É, Chakrabarti AK, et al. 25-Hydroxycholesterol inhibition of Lassa virus infection through aberrant GP1 glycosylation. mBio. 2016;7(6):e01808-16. doi:10.1128/mBio.01808-16.
   PubMed Web of Science ®Google Scholar
• Marcello A, Civra A, Milan Bonotto R, et al. The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients. Redox Biol. 2020;36:101682. doi:10.1016/j.redox.2020.101682.
   PubMed Web of Science ®Google Scholar
• Zu S, Deng YQ, Zhou C, et al. 25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor. Cell Res. 2020;30(11):1043–1045. doi:10.1038/s41422-020-00398-1.
   PubMed Web of Science ®Google Scholar
• Ablasser A, Hur S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids. Nat Immunol. 2020;21(1):17–29. doi:10.1038/s41590-019-0556-1.
   PubMed Web of Science ®Google Scholar
• Willemsen L, Chen HJ, van Roomen C, et al. Monocyte and macrophage lipid accumulation results in down-regulated type-I interferon responses. Front Cardiovasc Med. 2022;9:829877. doi:10.3389/fcvm.2022.829877.
   PubMed Web of Science ®Google Scholar
• Wang M, Casey PJ. Protein prenylation: Unique fats make their mark on biology. Nat Rev Mol Cell Biol. 2016;17(2):110–122. doi:10.1038/nrm.2015.11.
   PubMed Web of Science ®Google Scholar
• Yang S, Harding AT, Sweeney C, et al. Control of antiviral innate immune response by protein geranylgeranylation. Sci Adv. 2019;5(5):eaav7999. doi:10.1126/sciadv.aav7999.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Ding L, et al. Tim-4 reprograms cholesterol metabolism to suppress antiviral innate immunity by disturbing the Insig1-SCAP interaction in macrophages. Cell Rep. 2022;41(9):111738. doi:10.1016/j.celrep.2022.111738.
   PubMed Web of Science ®Google Scholar
• Lange PT, Darrah EJ, Vonderhaar EP, et al. Type I interferon counteracts antiviral effects of statins in the context of gammaherpesvirus infection. J Virol. 2016;90(7):3342–3354. doi:10.1128/JVI.02277-15.
   PubMed Web of Science ®Google Scholar
• del Real G, Jiménez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med. 2004;200(4):541–547. doi:10.1084/jem.20040061.
   PubMed Web of Science ®Google Scholar
• Gower TL, Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother. 2001;45(4):1231–1237. doi:10.1128/AAC.45.4.1231-1237.2001.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44(1):117–125. doi:10.1002/hep.21232.
   PubMed Web of Science ®Google Scholar
• Shrivastava-Ranjan P, Flint M, Bergeron E, et al. Statins suppress ebola virus infectivity by interfering with glycoprotein processing. mBio. 2018;9(3). doi:10.1128/mBio.00660-18.
   PubMed Web of Science ®Google Scholar
• Rothwell C, Lebreton A, Young Ng C, et al. Cholesterol biosynthesis modulation regulates dengue viral replication. Virology. 2009;389(1–2):8–19. doi:10.1016/j.virol.2009.03.025.
   PubMed Web of Science ®Google Scholar
• Martínez-Gutierrez M, Castellanos JE, Gallego-Gómez JC. Statins reduce dengue virus production via decreased virion assembly. Intervirology. 2011;54(4):202–216. doi:10.1159/000321892.
   PubMed Web of Science ®Google Scholar
• Troeman DP, Postma DF, van Werkhoven CH, et al. The immunomodulatory effects of statins in community-acquired pneumonia: A systematic review. J Infect. 2013;67(2):93–101. doi:10.1016/j.jinf.2013.04.015.
   PubMed Web of Science ®Google Scholar
• Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: A cohort study. PLoS One. 2009;4(11):e8087. doi:10.1371/journal.pone.0008087.
   PubMed Web of Science ®Google Scholar
• Atamna A, Babitch T, Bracha M, et al. Statins and outcomes of hospitalized patients with laboratory-confirmed 2017-2018 influenza. Eur J Clin Microbiol Infect Dis. 2019;38(12):2341–2348. doi:10.1007/s10096-019-03684-y.
   PubMed Web of Science ®Google Scholar
• Kondo C, Atsukawa M, Tsubota A, et al. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J Viral Hepat. 2012;19(9):615–622. doi:10.1111/j.1365-2893.2011.01584.x.
   PubMed Web of Science ®Google Scholar
• Sezaki H, Suzuki F, Akuta N, et al. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology. 2009;52(1):43–48. doi:10.1159/000213504.
   PubMed Web of Science ®Google Scholar
• Yang YH, Chen WC, Tsan YT, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015;63(5):1111–1117. doi:10.1016/j.jhep.2015.07.006.
   PubMed Web of Science ®Google Scholar
• Ma X, Sun D, Li C, Ying J, Yan Y. Statin use and virus-related cirrhosis: A systemic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41(5):533–542. doi:10.1016/j.clinre.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Choi WM, Kim HJ, Jo AJ, et al. Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. Liver Int. 2021;41(11):2777–2785. doi:10.1111/liv.15011.
   PubMed Web of Science ®Google Scholar
• Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021;10:e73873. doi:10.7554/eLife.73873.
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176–187.e4. doi:10.1016/j.cmet.2020.06.015.
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Mohammadi SM, Banach M, et al. Improved COVID-19 outcomes following statin therapy: An updated systematic review and meta-analysis. Biomed Res Int. 2021;2021:1901772. doi:10.1155/2021/1901772.
   PubMed Web of Science ®Google Scholar
• Assefi M, Bijan Rostami R, Ebrahimi M, et al. Potential use of the cholesterol transfer inhibitor U18666A as an antiviral drug for research on various viral infections. Microb Pathog. 2023;179:106096. doi:10.1016/j.micpath.2023.106096.
   PubMed Web of Science ®Google Scholar
• Glitscher M, Martín DH, Woytinek K, et al. Targeting cholesterol metabolism as efficient antiviral strategy against the hepatitis E virus. Cell Mol Gastroenterol Hepatol. 2021;12(1):159–180. doi:10.1016/j.jcmgh.2021.02.002.
   PubMed Web of Science ®Google Scholar
• Pawar A, Pal A, Goswami K, et al. Molecular basis of quercetin as a plausible common denominator of macrophage-cholesterol-fenofibrate dependent potential COVID-19 treatment axis. Results Chem. 2021;3:100148. doi:10.1016/j.rechem.2021.
   PubMedGoogle Scholar
• Pollock S, Nichita NB, Böhmer A, et al. Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci USA. 2010;107(40):17176–17181. doi:10.1073/pnas.1009445107.
   PubMed Web of Science ®Google Scholar
• Liu Y, Wei Z, Ma X, et al. 25-Hydroxycholesterol activates the expression of cholesterol 25-hydroxylase in an LXR-dependent mechanism. J Lipid Res. 2018;59(3):439–451. doi:10.1194/jlr.M080440.
   PubMed Web of Science ®Google Scholar
• Barkas F, Milionis H, Anastasiou G, et al. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019? Med Hypotheses. 2021;146:110452. doi:10.1016/j.mehy.2020.
   PubMed Web of Science ®Google Scholar
• Liou J-W, Mani H, Yen J-H. Viral hepatitis, cholesterol metabolism, and cholesterol-lowering natural compounds. Int J Mol Sci. 2022;23(7):3897. doi:10.3390/ijms23073897.
   PubMed Web of Science ®Google Scholar